ArticleCancer medicine2025
Multiparametric MRI-Based Intratumoral and Peritumoral Radiomics for Distinguishing Solitary Intrahepatic Mass-Forming Cholangiocarcinoma From Colorectal Liver Metastases.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predictive imaging in abdominal oncology: current trends and future directions.Japanese journal of radiology · 2026Review
- Multiparametric MRI-Based Intratumoral and Peritumoral Radiomics for Distinguishing Solitary Intrahepatic Mass-Forming Cholangiocarcinoma From Colorectal Liver Metastases.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo establish a model based on intratumoral and peritumoral radiomics for preoperatively differentiating solitary intrahepatic mass-forming cholangiocarcinoma (IMCC) lesions from colorectal cancer liver metastases (CRLM).
methodsPreoperative MRI scans from IMCC patients were retrospectively obtained from three academic medical centers. Radiomics features were extracted from the intratumoral and multiple peritumoral regions. After feature selection, the optimal peritumoral range was determined. The radiomics model was developed by integrating both single-sequence and multisequence models through probabilistic ensemble learning. Significant variables from clinical imaging features, radiomics, were integrated into a combined model, and its performance was evaluated using the area under the receiver operating characteristic curve (AUC).
resultsA total of 170 patients (93 IMCC, 77 CRLM) comprised the training cohort, and 42 (23 IMCC, 19 CRLM) formed the external validation cohort. The Combined model achieved superior AUCs in training (0.978 [95% CI: 0.971-0.985]) and validation (0.940 [0.899-0.968]), outperforming radiomics (training: 0.947 [(95% CI: 0.932-0.961]); validation: 0.908 [(95% CI: 0.861-0.943)]) and Clin-Imag models (training: 0.858 [95% CI: 0.831-0.880]; validation: 0.842 [95% CI: 0.786-0.889]) (DeLong test, p = 0.001). SHAP analysis identified DWI-based 5-mm peritumoral features and clinical-imaging variables (e.g., lesion location and bile duct dilation) as key discriminators.
conclusionsThe combined model integrating clinical-imaging variables and multiparametric MRI-derived intratumoral and 5-mm peritumoral radiomics features provides a non-invasive tool for distinguishing solitary IMCC from CRLM, offering potential clinical utility for guiding personalized treatment strategies and avoiding unnecessary invasive interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.